| Maria Gisela Gallardo, MD | |
|
Oakland Family Services, 114 Orchard Lake Road, Pontiac, MI 48341-4834 | |
| (248) 858-7766 | |
| Not Available |
| Full Name | Maria Gisela Gallardo |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | Oakland Family Services, Pontiac, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194816835 | NPI | - | NPPES |
| 4658001 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 4301067408 (Michigan) | Primary |
| Entity Name | West Michigan Community Mental Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275646309 PECOS PAC ID: 8426046855 Enrollment ID: O20040504001447 |
News Archive
Hologic, a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the U.S. Food and Drug Administration has approved Hologic's pharmaceutical named Makena, formerly known as Gestiva.
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2011.
Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer.
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation," led by Bonnie W. Ramsey, MD of Seattle Children's Research Institute and the University of Washington, were published today in the New England Journal of Medicine.
Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.
› Verified 7 days ago
| Entity Name | Bay-arenac Behavioral Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154439438 PECOS PAC ID: 5496706228 Enrollment ID: O20050209000187 |
News Archive
Hologic, a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the U.S. Food and Drug Administration has approved Hologic's pharmaceutical named Makena, formerly known as Gestiva.
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2011.
Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer.
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation," led by Bonnie W. Ramsey, MD of Seattle Children's Research Institute and the University of Washington, were published today in the New England Journal of Medicine.
Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maria Gisela Gallardo, MD Oakland Family Services, 114 Orchard Lake Road, Pontiac, MI 48341-5641 Ph: (248) 858-7766 | Maria Gisela Gallardo, MD Oakland Family Services, 114 Orchard Lake Road, Pontiac, MI 48341-4834 Ph: (248) 858-7766 |
News Archive
Hologic, a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the U.S. Food and Drug Administration has approved Hologic's pharmaceutical named Makena, formerly known as Gestiva.
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2011.
Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer.
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation," led by Bonnie W. Ramsey, MD of Seattle Children's Research Institute and the University of Washington, were published today in the New England Journal of Medicine.
Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.
› Verified 7 days ago
Dr. Shahid Jamil, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 44555 Woodward Ave, Ste 405, Pontiac, MI 48341 Phone: 248-333-7100 Fax: 248-858-7224 | |
Prasanth Talluri, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 461 W Huron St, Pontiac, MI 48341 Phone: 248-857-6700 | |
Lalitha Vemuri, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 28 W Lawrence St, Pontiac, MI 48342 Phone: 248-858-5326 | |
Naushad Makbulbhai Mansuri, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 461 W Huron St, Pontiac, MI 48341 Phone: 248-857-7200 | |
Rao Vallabhaneni, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 35 W Huron St, Pontiac, MI 48342 Phone: 248-745-4900 Fax: 248-745-6872 | |
Dr. Oleksiy Levantsevych, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 461 W Huron St, Pontiac, MI 48341 Phone: 248-857-7200 |